Government Affairs
Refine Search
Pharmaceutical
Proposals that will in future enable more the UK's National Health Service patients to access innovative medicines were set out by Secretary of State for Health Andrew Lansley yesterday. The plans for pricing drugs according to how they benefit patients, the NHS and wider society were published in a consultation: A new value-based approach to the pricing of branded medicines. 17 December 2010
Pharmaceutical
Mexico's future health care expenditure hinges on the country's upcoming elections, scheduled for 2012, which predictably hold the key to a number of changes in government spending decisions. 17 December 2010
Pharmaceutical
Under plans to be announced later this week, Andrew Lansley, UK Secretary of State for Health, will announce details of a new mechanism for deciding how much the National Health Service will pay for costly new drugs, which puts the onus on doctors to decide whether they are affordable. 14 December 2010
Generics
European Commission president Jose Manuel Barroso revealed last Friday that a trade and investment agreement between the European Union and India would be concluded in the first part of next year. Negotiations for such a Free Trade Agreement (FTA) were launched in June 2007. 13 December 2010
Generics
Brazil, one of the major emerging powers of the world, is marking its presence in almost every dimension of the global economy, including the generic drugs industry. The generics industry has registered a significant growth rate over the last few years. 13 December 2010
Pharmaceutical
In Business Monitor International's Asia Pacific Business Environment Ratings (BERs) for the first quarter of 2011, Pakistan remains 16th, having dropped one place compared with the previous quarter due to the addition of a more attractive market Sri Lanka to their proprietary ratings system. Globally, Pakistan ranks 75th of the 83 markets surveyed. 13 December 2010
Pharmaceutical
The pharmaceutical industry must prepare itself for an increasingly draconian drug pricing environment. While governments in most of the world's developed economies already regulate the prices of most prescription drugs, their control over prices will tighten in the future. 10 December 2010
Pharmaceutical
With total revenues of $15.3 billion in 2009, the Russian pharmaceutical market is one of the largest in the world. The market is anticipated to remain on a path of dynamic growth from 2010 to 2016 mainly due to multiple initiatives of the Russian government. However, in the short term, the process of implementing legislative changes could slightly restrain the market's development. 9 December 2010
Pharmaceutical
A confidential Trans-Pacific Partnership Agreement (TPPA) negotiating paper authored by New Zealand suggests that the trade pact's patent and copyright provisions be no more stringent than existing global standards. Warning that the New Zealand position still poses some risks for access to medicines, US consumer advocacy group Public Citizen applauds this direct challenge to the monopoly interests of major pharmaceutical corporations. 7 December 2010
Pharmaceutical
US President Barack Obama last Friday announced the successful resolution of the outstanding issues with the US-Korea trade agreement, setting the stage for consideration of the agreement by Congress in the coming months. 7 December 2010
Pharmaceutical
Addressing health inequalities across Europe is a key challenge for improving care for patients. There is wide variability between member states in the speed with which valuable innovative medicines become available to patients; and then further variability in uptake of medicines between countries and between disease areas. 7 December 2010
Biotechnology
The UK Chancellor of the Exchequer, George Osborne's announcement this week of a 'brick-by-brick' dismantling of the barriers holding back British growth, promising a so-called 'patent box,' a new 10% rate of corporation tax (versus the standard 28% rate) to be levied on profits from new products developed and generated in Britain, has been broadly welcomed. Indeed, drugs giant GlaxoSmithKline followed the news by announcing a subsequent 500 million ($780 million) investment in the UK (The Pharma Letter November 30). However, some have reservations. 2 December 2010
Pharmaceutical
China will lower retail price caps on 17 kinds of pharmaceutical products by an average 19% effective December 12, the country's economic planner and price regulator the National Development and Reform Commission (NDRC) said in a statement on Tuesday, reported by the Xinhau news agency. These will mainly impact drugs from multinational producers. 1 December 2010
Pharmaceutical
In a letter addressed to US Senator Charles Grassley, the vaccine safety non-profit organization S.A.N.E Vax congratulated the senator on his recent efforts to examine ethical questions raised by National Cancer Institute (NCI) employees accepting extensive travel sponsored by private companies and identified two senior NCI scientists who knowingly promote unreliable human papillomavirus (HPV) tests for patient care, and the development/monitoring of genotype-specific HPV vaccines to promote an unproven virology-based cervical cancer prevention business agenda. 30 November 2010
Pharmaceutical
Australia's Senate Community Affairs Committee has recommended that the threshold for Federal Cabinet approval for listing new medicines on the Pharmaceutical Benefits Scheme (PBS) be increased. In its report released last week, the Committee recommended that the threshold should be immediately increased from its current A$10 million ($9.8 million) to a level reflecting its original 2001 value and that the threshold should be indexed annually to maintain its real value. 29 November 2010
Pharmaceutical
Germany has retained its position as the most attractive pharmaceutical market in Western Europe, out of the 10 countries surveyed in Business Monitor International's Business Environment Ratings (BER) for fourth-quarter 2010. The ratings criteria serve to reinforce BMI's estimation of the country's potential owing to its strong emphasis on the regulatory environment. 29 November 2010
Generics
In Business Monitor International's fourth-quarter 2010 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.5 out of 100. The attractiveness of the region to pharmaceutical firms stems from the fact that its countries are key revenue sources for Big Pharma, particularly for companies selling high-end products, as per-capita spending is substantially above that of emerging markets. 26 November 2010
Pharmaceutical
Patients must have better access to high-quality information on prescription medicines in the future, said Members of the European Parliament (MEPs) voting on draft legislation yesterday. This means providing objective information on a drug's characteristics and the treated disease or condition, while preventing unsolicited information or disguised advertising. 25 November 2010
Pharmaceutical
Despite the overhaul of Indonesia's regulatory system, its pharmaceutical sector remains a difficult position. Inadequate patent laws, uncertain government pricing policy and strong domestic capacity are largely to blame, notes a new report from Business Monitor International. 24 November 2010
Biotechnology
Australia's Parliament today passed the National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010. The Bill legislates price cuts to PBS medicines agreed in the Memorandum of Understanding between Medicines Australia and the Commonwealth government. 23 November 2010
Pharmaceutical
The nomination of Robert F Kennedy Jr — known as RFK Jr — for the role of US Secretary of the Department of Health and Human Services (HHS) President-elect Donald Trump sent shares in vaccine companies sharply downwards. 22 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
The Danish government’s newly-unveiled health reform has been praised for tackling chronic disease care and health inequalities while driving health innovation. 18 November 2024
Pharmaceutical
New research published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across member states and compares Europe to other regions of the world. 18 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Pharmaceutical
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole. 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research investments. 11 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 million) pledge to develop the country’s medicine manufacturing capabilities. 6 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies. 4 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness. 30 October 2024
Pharmaceutical
HOPO Therapeutics has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA). 29 October 2024
Pharmaceutical
The Danish government has presented part of the plan for a future life science strategy, which has been welcomed by the industry. 28 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze